Wall Street Analyst Ratings: Uber Initiated and Thermo Fisher Upgraded
Yahoo Finance ·
On September 9, 2026, Wall Street analysts issued several notable rating changes and new coverages. UBS upgraded Thermo Fisher to Buy from Neutral, raising its target price to $730, citing a durable path back to 5%-6%-plus organic growth by 2027. BofA upgraded Figure Technology to Neutral with a $49 price target, while Wells Fargo lifted Martin Marietta to Overweight with a $609 target based on recent acquisitions and pricing momentum. Morgan Stanley moved Lineage to Overweight, and Jefferies upgraded Summit Therapeutics to Buy ahead of upcoming clinical data. Conversely, JPMorgan downgraded Dyne Therapeutics to Underweight following a peer trial setback, and Wells Fargo lowered three construction materials names, including Vulcan Materials, to Underweight on a cautious 2027 outlook. In new coverage, Scotiabank initiated both Uber and DoorDash with Outperform ratings, setting respective price targets of $100 and $275, while Loop Capital started Affirm with a Buy rating and a $105 target.
AI 시장 분석
Wall Street major investment banks have released updates on rating upgrades and downgrades for specific stocks. UBS raised Thermo Fisher's price target to $730, citing improving pharmaceutical and biotech funding. Conversely, Wells Fargo downgraded construction materials stocks like Vulcan Materials due to high interest rates and declining government spending. Investors must simultaneously examine individual corporate fundamentals and macroeconomic variables.
상승 영향
- Biotech — UBS raised Thermo Fisher (TMO) price target to $730 and forecasted improved pharma/biotech funding and bioprocessing demand
- Mobility — Scotiabank initiated coverage on Uber and DoorDash with price targets of $100 and $275, respectively, praising margin expansion
하락 영향
- Construction Materials — Wells Fargo downgraded three construction materials stocks, including Vulcan Materials, to Underweight, citing declining government spending and high interest rates in 2027
- Biotech — JPMorgan downgraded Dyne Therapeutics to Underweight, pointing to pipeline risks caused by Novartis clinical trial failures
DYAX 전담 분석
Research calls from Wall Street analysts directly drive short-term supply-demand dynamics and volatility for individual stocks. UBS's price target hike for Thermo Fisher (from $540 to $730) reflects 5-6% organic growth, stimulating investment sentiment in the related pharma and biotech sector.
The bullish scenario is that related companies post strong earnings driven by improved pharma/biotech funding and expanding mobility demand. The bearish scenario is that traditional industrial groups, such as construction materials and chemicals, experience sluggish earnings due to high interest rates and government spending tightening. Key indicators to watch are the Federal Reserve's rate path and whether companies achieve their 2027 earnings guidance.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
288 participants
Related News
- Should You Grab Nebius In Anticipation of Full Capacity Pricing?
- Seagate Technology and Western Union have been highlighted as Zacks Bull and Bear of the Day
- Bandwidth, Google, and ServiceNow Named Finalists for AFP 2026 Pinnacle Awards
- MercadoLibre Shares Decline Following News of Corporate Debt Market Utilization
- Apple Increases Streaming Fees as Next-Gen iPhone Faces $500 Price Surge
- Analyzing Amazon’s (AMZN) Reinvestment Flywheel in the AI Era
